Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and toxicity of Nimotuzumab combined with VMAT in the treatment of
elderly patients with nasopharyngeal carcinoma (> 70 years old), and to provide high-level
clinical evidence for the optimal treatment of elderly patients with nasopharyngeal
carcinoma.